Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Viridian Therapeutics, Inc. (VRDN) had Stock-Based Compensation of $67.17M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$0.31M |
|
$-237.73M |
|
-- |
|
$0.31M |
|
$254.76M |
|
$-254.45M |
|
$16.72M |
|
$-237.73M |
|
$-237.73M |
|
$-237.73M |
|
$-237.73M |
|
$-237.73M |
|
$-237.73M |
|
$-254.45M |
|
$-265.42M |
|
44.76M |
|
44.76M |
|
$-5.31 |
|
$-5.31 |
|
| Balance Sheet Financials | |
$486.48M |
|
$1.67M |
|
$3.95M |
|
$490.42M |
|
$26.64M |
|
$20.20M |
|
$21.77M |
|
$48.40M |
|
$235.51M |
|
$442.02M |
|
$442.02M |
|
53.99M |
|
| Cash Flow Statement Financials | |
$-184.17M |
|
$-94.25M |
|
$225.67M |
|
$155.58M |
|
$102.83M |
|
$-52.75M |
|
|
Stock-Based Compensation |
$67.17M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.26 |
|
-- |
|
-- |
|
0.04 |
|
0.05 |
|
100.00% |
|
-81035.03% |
|
-81035.03% |
|
-84528.02% |
|
-75711.46% |
|
-75711.46% |
|
$-185.07M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-100.95% |
|
-53.78% |
|
-48.48% |
|
-51.43% |
|
$8.19 |
|
$-4.14 |
|
$-4.12 |
|